Search results
Found 6977 matches for
University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
©
Credit: University of Oxford, John Cairns
James Gilchrist
MBioch, MBBS, MRCPCH, DPhil, PGDip Paediatric Infectious Diseases James Gilchrist - Wellcome Career Development Fellow
Sir Andrew Pollard
BSc MBBS PhD (Lond), DIC, MRCP (UK), FHEA, FRCPCH, MA, FMedSci, FRS Sir Andrew Pollard - Ashall Professor of Infection & Immunity